Events
-
MAY 26 2020
-
-
DEC 05 2019
ASH 2019 (Orlando): Researchers to Present Posters on Efficacy of ONC201 in AML and Myelofibrosis
A) ONC201 and ONC212 efficacy in AML Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia. Michael Andreeff, MD, PhD and Jo Ishizawa, MD, PhD. Department of Leukemia, The University of Texas MD Anderson Cancer Center Number: 2562, Link: https://ash.confex.com/ash/2019/webprogram/Paper127101.html Sunday, December 8, 2019, 6:00 PM-8:00 PM Hall B, Level 2 (Orange County Convention Center)
-
-
OCT 14 2019
10/12/2019 Oncoceutics Volunteers at NBTS Race for Hope Philadelphia
The Oncoceutics Team in front of the Race for Hope registration tent at Saturday's 14th Annual Race for Hope - Philadelphia.-
-
OCT 09 2019
10/6/2019: Velocity, Columbia’s Ride to End Cancer
Oncoceutics COO Lee Schalop gets ready to ride in support of the Brain Power team led by Andrew Lassman, MD, principal investigator of the company’s "ONC201 in Adults With Recurrent H3 K27M-mutant Glioma” study as part of 2019 Velocity, Columbia’s Ride to End Cancer.-
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.